Proton pump inhibitor-responsive oesophageal eosinophilia: An entity challenging current diagnostic criteria for eosinophilic oesophagitis

Gut

Volumn 65, Issue 3, 2016, Pages 521-531

  Molina Infante, Javier ^a   Bredenoord, Albert J ^b   Cheng, Edaire ^c   Dellon, Evan S ^d   Furuta, Glenn T ^e   Gupta, Sandeep K ^f   Hirano, Ikuo ^g   Katzka, David A ^h   Moawad, Fouad J ⁱ   Rothenberg, Marc E ^j   Schoepfer, Alain ^k   Spechler, Stuart J ^c   Wen, Ting ^j   Straumann, Alex ^l   Lucendo, Alfredo J ^m  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e CHILDREN S HOSPITAL COLORADO   (United States)

^f INDIANA UNIVERSITY   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h MAYO CLINIC   (United States)

ⁱ WALTER REED ARMY MEDICAL CENTER   (United States)

^j CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^k LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^l Chairman Swiss EoE Research Group   (Switzerland)

^m Hospital General de Tomelloso   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN 3; ESOMEPRAZOLE; INTERLEUKIN 13; INTERLEUKIN 5; INTERLEUKIN 8; LANSOPRAZOLE; MONOCYTE CHEMOTACTIC PROTEIN 1; MUCIN 4; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANTES; STEROID; TRANSCRIPTION FACTOR RUNX2;

ALOX15 GENE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CDH26 GENE; CLINICAL EFFECTIVENESS; CPA3 GENE; DIAGNOSTIC TEST; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; DSG1 GENE; ENDOSCOPY; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; ESOPHAGUS DISEASE; FLG GENE; GASTROESOPHAGEAL REFLUX; GENE; GENE EXPRESSION; GENE LOCUS; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; MUC4 GENE; PHARMACOLOGICAL BLOCKING; POSTN GENE; PRIORITY JOURNAL; PROGNOSIS; PROTON PUMP INHIBITOR RESPONSIVE ESOPHAGEAL EOSINOPHILIA; STEROID THERAPY; SYMPTOM; TNFAIP6 GENE; TPSAB2 GENE; TREATMENT DURATION; TREATMENT RESPONSE; DIFFERENTIAL DIAGNOSIS; IMMUNOLOGY; PRACTICE GUIDELINE;

DIAGNOSIS, DIFFERENTIAL; EOSINOPHILIC ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS;

EID: 84960338266     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310991     Document Type: Article

References (59)

1. Kandulski A, Malfertheiner P. Gastroesophageal reflux disease-from reflux episodes to mucosal inflammation. Nat Rev Gastroenterol Hepatol 2011;9:15-22.
2. Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011;128:3-20.
3. Kia L, Hirano I. Distinguishing GERD from eosinophilic esophagitis: concepts and controversies. Nat Rev Gastroenterol Hepatol 2015;12:379-86.
4. Molina-Infante J, Ferrando-Lamana L, Ripoll C, et al. Esophageal eosinophilic infiltration responds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol 2011;9:110-17.
5. Straumann A, Aceves SS, Blanchard C, et al. Pediatric and adult eosinophilic esophagitis: similarities and differences. Allergy 2012;67:477-90.
6. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133:1342-63.
7. Dellon ES, Speck O, Woodward K, et al. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. Am J Gastroenterol 2013;108:1854-60.
8. Moawad FJ, Schoepfer AM, Safroneeva E, et al. Eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia have similar clinical, endoscopic and histological findings. Aliment Pharmacol Ther 2014;39:603-8.
9. Molina-Infante J, Rivas MD, Hernandez-Alonso M, et al. Remission in proton pump inhibitor-responsive esophageal eosinophilia correlates with down regulation of eotaxin-3 and TH2 cytokines, similarly to eosinophilic esophagitis after steroids. Aliment Pharmacol Ther 2014;40:955-65.
10. Iwakura N, Fujiwara Y, Tanaka F, et al. Basophil infiltration in eosinophilic oesophagitis and proton pump inhibitor-responsive oesophageal eosinophilia. Aliment Pharmacol Ther 2015;41:776-84.
11. Warners MJ, van Rhijn BD, Curvers WL, et al. PPI-responsive esophageal eosinophilia cannot be distinguished from eosinophilic esophagitis by endoscopic signs. Eur J Gastroenterol Hepatol 2015;27:506-11.
12. Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut 2013;62:489-95.
13. Collins MH. Histopathologic features of eosinophilic esophagitis and eosinophilic gastrointestinal diseases. Gastroenterol Clin North Am 2014;43:257-68.
14. Dellon ES, Chen X, Miller CR, et al. Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis. Am J Gastroenterol 2012;107:1503-11.
15. Dellon ES, Speck O, Woodward K, et al. Markers of eosinophilic inflammation for diagnosis of eosinophilic esophagitis and proton pump inhibitor-responsive esophageal eosinophilia: a prospective study. Clin Gastroenterol Hepatol 2014;12:2015-22.
16. Sayej WN, Patel R, Baker RD, et al. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2009;49:1-7.
17. Isomoto H, Nishi Y, Wang A, et al. Mucosal concentrations of proinflammatory cytokines and chemokines at gastric cardia: implication of Helicobacter pylori infection and gastroesophageal reflux. Am J Gastroenterol 2004;99:1063-8.
18. Rothenberg ME. Molecular, genetic, and cellular bases for treating eosinophilic esophagitis. Gastroenterology 2015;148:1143-57.
19. Wen T, Stucke EM, Grotjan TM, et al. Molecular diagnosis of eosinophilic esophagitis by gene expression profiling. Gastroenterology 2013;145:1289-99.
20. Moawad FJ, Wells JM, Johnson RL, et al. Comparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2015;42:231-8.
21. van Rhijn BD, Weijenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol 2014;12:1815-23.
22. Wen T, Dellon ES, Moawad FJ, et al. Transcriptome analysis of proton pump inhibitor-responsive esophageal eosinophilia reveals proton pump inhibitor-reversible allergic inflammation. J Allergy Clin Immunol 2015;135:187-97.
23. Butz BK, Wen T, Gleich GJ, et al. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology 2014;147:324-33.e5.
24. Rothenberg ME, Spergel JM, Sherrill JD, et al. Common variants at 5g22 associate with pediatric eosinophilic esophagitis. Waf Genef 2010;42:289-91.
25. Kottyan LC, Davis BP, Sherrill JD, et al. Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease. Waf Genef 2014;46:895-900.
26. Sleiman PMA, Wang ML, Cianferoni A, et al. GWAS identifies four novel eosinophilic esophagitis loci. Waf Commun 2014;5:5593.
27. Ngo P, Furuta GT, Antonioli DA, et al. Eosinophils in the esophagus-peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol 2006;101:1666-70.
28. Desai TK, Stecevic V, Chang CH, et al. Association of eosinophilic inflammation with esophageal food impaction in adults. Gastrointest Endosc 2005;61:795-801.
29. Dranove JE, Horn DS, Davis MA, et al. Predictors of response to proton pump inhibitor therapy among children with significant esophageal eosinophilia. J Pediatr 2009;154:96-100.
30. Peterson KA, Thomas KL, Hilden K, et al. Comparison of esomeprazole to aerosolized, swallowed fluticasone for eosinophilic esophagitis. Dig DisSci 2010;55:1313-19.
31. Moawad FJ, Veerappan GR, Dias JA, et al. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol 2013;108:366-72.
32. Vazguez-Elizondo G, Ngamruengphong S, Khrisna M, et al. The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. Aliment Pharmacol Ther 2013;38:1312-19.
33. Gutierrez-Junguera C, Fernandez-Fernandez S, Cilleruelo ML, et al. High prevalence of response to proton pump inhibitor treatment in children with esophageal eosinophilia. J Pediatr Gastroenterol Nutr Published Online First 23 Oct. 2015. doi: 10.1097/MPG.0000000000001019
34. Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histological remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol Published Online First: 3 Aug. 2015. doi: 10.1016/j.cgh.2015.07.041
35. Dohil R, Newbury RO, Aceves S. Transient PPI responsive esophageal eosinophilia may be a clinical sub-phenotype of pediatric eosinophilic esophagitis. Dig Dis Sci 2012;57:1413-19.
36. Schroeder S, Capocelli KE, Masterson JC, et al. Effect of proton pump inhibitor on esophageal eosinophilia. J Pediatr Gastroenterol Nutr 2013;56:166-72.
37. Molina-Infante J, Rodriguez-Sanchez J, Martinek J, et al. Long-term loss of response in proton pump inhibitor-responsive esophageal eosinophilia is uncommon and influenced by CYP2C19 genotype and rhinoconjunctivitis. Am J Gastroenterol Published Online First: 29 Sep. 2015. doi: 10.1038/ajg.2015.314
38. Cheng E, Souza RF, Spechler SJ. Eosinophilic esophagitis: interactions with gastroesophageal reflux disease. Gastroenterol Clin North Am 2014;43:243-56.
39. Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 2009;54:2312-17.
40. Cheng E, Zhang X, Huo X, et al. Omeprazole blocks eotaxin-3 expression by oesophageal sguamous cells from patients with eosinophilic oesophagitis and GORD. Guf 2013;62:824-32.
41. Zhang X, Cheng E, Huo X, et al. Omeprazole blocks STAT6 binding to the eotaxin-3 promoter in eosinophilic esophagitis cells. PLoS One 2012;7:e50037.
42. Park JY, Zhang X, Nguyen N, et al. Proton pump inhibitors decrease eotaxin-3 expression in the proximal esophagus of children with esophageal eosinophilia. PLoS One 2014;9:e101391.
43. Sherrill JD, Kc K, Wu D, et al. Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. Mucosal Immunol 2014;7:718-29.
44. van Rhijn BD, Verheij J, van den Bergh Weerman MA, et al. Histological response to fluticasone propionate in patients with eosinophilic esophagitis is associated with improved functional esophageal mucosal integrity. Am J Gastroenterol 2015;110:1289-97.
45. Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol 2007;102:1301-6.
46. Krarup AL, Villadsen GE, Mejlgaard E, et al. Acid hypersensitivity in patients with eosinophilic oesophagitis. Scand J Gastroenterol 2010;45:273-81.
47. Francis DL, Foxx-Orenstein A, Arora AS, et al. Results of ambulatory pH monitoring do not reliably predict response to therapy in patients with eosinophilic esophagitis. Aliment Pharmacol Ther 2012;35:300-7.
48. Abe Y, lijima K, Ohara S, et al. A Japanese case series of 12 patients with oesophageal eosinophilia. J Gastroenterol 2011;46:25-30.
49. Levine J, Lai J, Edelman M, et al. Conservative long-term treatment of children with eosinophilic esophagitis. Ann Allergy Asthma Immunol 2012;108:363-6.
50. Sodikoff J, Hirano I. Proton pump inhibitor-responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis. J Allergy Clin Immunol Published Online First: 25 Aug. 2015. doi: 10.1016/j.jad.2015.07.008
51. Lucendo AJ, Arias A, Gonzalez-Cervera J, et al. Dual response to dietary/topical steroid and PPI therapy in adult patients with eosinophilic esophagitis. J Allergy Clin Immunol 2015. doi: 10.1016/j.jaci.2015.07.033
52. Katzka D. Eosinophilic esophagitis and proton pump-responsive esophageal eosinophilia: what is in a name? Clin Gastroenterol Hepatol 2014;12:2023-5.
53. Dellon ES, Gonsalves N, Hirano I, et al. ACG Clinical Guideline: evidence based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis. Am J Gastroenterol 2013;108:679-92.
54. Dellon ES, Liacouras CA. Advances in clinical management of eosinophilic esophagitis. Gastroenterology 2014;147:1238-54.
55. Chuang MY, Chinnaratha MA, Hancock DG, et al. Topical steroid therapy for the treatment of eosinophilic esophagitis (EoE): a systematic review and meta-analysis. Clin Transl Gastroenterol 2015;6:e82.
56. Arias A, Gonzalez-Cervera J, Tenias JM, et al. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology 2014;146:1639-48.
57. Calabrese C, Bortolotti M, Fabbri A, et al. Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment. Am J Gastroenterol 2005;100:537-42.
58. Straumann A, Schoepfer A. Update on basic and clinical aspects of eosinophilic oesophagitis. Gut 2014;63:1355-63.
59. Zhang X, Huo X, Yu C, et al. Omeprazole and fluticasone inhibit IL-13-stimulated eotaxin-3 expression by esohageal epithelial cells through different mechanisms and with additive effects: rationale for combining PPIs with topical steroids for EoE patients. Gastroenterology 2015;148(Suppl 1):S-51.